Abstract
Peru has the highest incidence of human cystic echinococcosis (CE) in South America and most cases are reported in the Central and Southern Peruvian Andes, including the Cusco region. We reviewed medical records of patients with CE admitted between 2010-2019 to a level 2 Hospital in Sicuani, to collect data on the surgical management and disease recurrence in the Canchis province of Cusco. Records of 115 patients were analyzed in detail. The median age was 25 years (IQR, 16-46) and 60% were female. Most patients (68.7%) presented with a single liver cyst. The Gharbi classification was used in 75/107 (70.1%) patients with an ultrasound and 91/142 cysts (64.8%). Thirty one (34.1%) were classified as Gharbi I, 33 (36.3%) Gharbi II, 21 (23.1%) Gharbi III, and 6 (6.6%) Gharbi IV. Pre-surgical complications were reported in 41.7%. One hundred two patients underwent surgery. In 46.1%, one cyst spillage prevention measure was documented, 5.9% had two, and one had the three recommended measures. Post-surgical cyst recurrence was reported in 16.5% at a median 32.3 months (IQR, 3.9-46.6) and readmissions in 12.7%. In the multivariable analysis, having ≥3 cysts (OR 9.5, 95% CI 1.3-85.5), having two pre-surgical complications (OR 12.6, 95% CI 1.8-125.6), and receiving pre-surgical albendazole (OR 5.2, 95% CI 1.3-23.9) were associated with cyst recurrence. Advanced and complicated CE disease and post-surgical recurrence were common in Sicuani. Standardization of ultrasound staging-guided clinical management along with surgical spillage prevention measures could effectively decrease the disease burden linked to clinical care, improving outcomes and decreasing costs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Bologna Master Thesis funding from the Deparment of Education of the University of Basel, Switzerland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Ethics Committee of Northern and Central Switzerland (Ethikkommission Nordwest- und Zentralschweiz, EKNZ) and the Institutional Ethics Committee (Comite Institucional de Etica en Investigacion) of the Universidad Peruana Cayetano Heredia in Lima, Peru.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
